Key result
Antihypertensive therapy increases 5-year survival in malignant hypertension from 0% to 75%, but its benefits against coronary heart disease are less obvious than for stroke.
Antihypertensive therapy significantly improves survival and reduces stroke and heart failure, but its suboptimal effect on coronary heart disease may be due to partially reversible pathology, inadequate blood pressure control, and adverse metabolic effects of certain drugs.
Answers are grounded in this paper and cite their sources.
Antihypertensive therapy markedly improves malignant hypertension survival yet offers less coronary protection than stroke reduction; leaves open mechanisms limiting CHD benefit.
The benefits of antihypertensive treatment are well-known. In malignant hypertension antihypertensive therapy has markedly improved prognosis and increased 5-year survival from 0% to 75%. In addition, the incidence of this severe form of hypertension has been shown to decrease significantly in some centers. In nonmalignant hypertension prognosis is also markedly improved thanks to antihypertensive therapy, with substantial reductions in the incidence of stroke and congestive heart failure, whereas the beneficial effects against coronary heart disease are less obvious. In addition, during recent years there has been some discussion about the J-curve phenomenon. There are several conceivable explanations behind the less than optimal outcome of antihypertensive therapy. Some of these will be discussed here, e.g. the fact that hypertension-induced pathology is only partially reversible. Moreover, in several intervention studies strict normotensive blood pressures have not been obtained during treatment. In addition, some of the antihypertensive drugs used may cause potentially negative effects, e.g. by increasing serum lipoproteins. Finally, the pathophysiology behind stroke and myocardial infarcts differ in several respects, and this may contribute to the less favourable effects of antihypertensive treatment on coronary artery disease-morbidity as compared to stroke-morbidity.
No takes yet. Share an insight, caveat, or question.
Lennart Hansson (1989) conducted a review in Hypertension. Antihypertensive therapy was evaluated. Antihypertensive therapy increases 5-year survival in malignant hypertension from 0% to 75%, but its benefits against coronary heart disease are less obvious than for stroke.
Synapse has enriched 10 related papers. Consider them for comparative context: